Platinum-based therapy selects for an angiogenic enriched tumour micro-environment in High Grade Serous Ovarian Cancer
Download Almac Diagnostic Services Poster Presentation on ‘Platinum-based therapy selects for an angiogenic enriched tumour micro-environment in High Grade Serous Ovarian Cancer’.
1. The clinical and pre-clinical data discussed has potentially significant clinical implications in the management of treatment-relapsed HGSOC
2. Platinum-resistance (innate and acquired) in relapsed HGSOC is an indicator for response to anti-angiogenics
3. We have found that relapse post platinum-therapy in HGSOC is associated with an angiogenic biology
4. This clinical and pre-clinical data supports the use of anti-angiogenic agents in the first and second line setting in patients with innate and acquired resistance to platinum therapy, respectively
Your global partner for biomarker discovery, development & commercialisation.
We offer a range of genomics platform and chemistry options, alongside expert data sciences support and a full sample management service.
Clinical Trial Assays
Comprehensive development, validation & delivery service for research and clinical use assays from our global clinical laboratories in USA, Europe and APAC.
A collaborative Companion Diagnostic partnership approach with a deep understanding of client needs. We offer CDx development, manufacture & commercialisation services.